Evidence map›Paper›PMID 41742618›Full record

ReviewCurrent topics in medicinal chemistry2026

Recent Advances and Future Directions in 5-Fluorouracil Drug Delivery: A Comprehensive Review.

Ruobei Shu, Wuhao Wei, Zhaokai Li, Xinyu Wang, Yanting Kuang, Youfa Xu, Ruijuan Li, Xin Wu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruobei ShuDepartment of Pharmacy, Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China.
Wuhao WeiFormulation Department, Shanghai Wei Er Lab, Shanghai 201707, China.
Zhaokai LiDepartment of Pharmacy, Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China.
Xinyu WangFormulation Department, Shanghai Wei Er Lab, Shanghai 201707, China.
Yanting KuangFormulation Department, Shanghai Wei Er Lab, Shanghai 201707, China.
Youfa XuFormulation Department, Shanghai Wei Er Lab, Shanghai 201707, China.
Ruijuan LiDepartment of Pharmacy, Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China.
Xin WuDepartment of Pharmacy, Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China.

Funding

Inner Mongolia Autonomous Region No. NJYT-20-B26
6 · The paper itself

Abstract

Given the multiple challenges associated with the clinical use of 5-fluorouracil (5-FU), including pronounced fluctuations in plasma concentrations, significant interindividual metabolic variability, and frequent systemic adverse reactions, this study systematically examines the advantages and prospects of innovative 5-FU delivery strategies. These strategies aim to overcome its clinical limitations. To this end, molecular engineering approaches, such as Prodrug Technology, cocrystal technology, and conjugate design, are utilised to enhance permeability, solubility, and targeted release. In addition, microenvironmental regulation strategies modulate both systemic and tumor microenvironments, enhancing therapeutic efficacy and potentially reversing drug resistance. Furthermore, multifunctional, stimuli-responsive delivery carriers and devices now enable precise, intelligent drug release. Notably, as drug delivery technologies advance, emerging evidence suggests that single strategies cannot fully address the challenges of 5-FU administration. Therefore, multidimensional synergistic approaches significantly improve 5-FU bioavailability, reduce systemic toxicity, and optimize therapeutic outcomes. Looking forward, integrating multiple strategies within a multidisciplinary framework may offer a valuable paradigm for designing delivery systems for pyrimidine-based antimetabolite drugs.

Indexed as

Antimetabolites, AntineoplasticDrug Delivery SystemsFluorouracilNeoplasmsDrug CarriersHumansProdrugsAntimetabolites, AntineoplasticDrug CarriersFluorouracilProdrugs5-FUAntimetabolite drugsDrug delivery devicesDrug delivery technologiesDrug modification techniquesMicroenvironment

Identifiers

PMID41742618

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.